PUBLISHER: The Business Research Company | PRODUCT CODE: 2161096
PUBLISHER: The Business Research Company | PRODUCT CODE: 2161096
Per-and polyfluoroalkyl substances (PFAS)-free medical device materials refer to next-generation polymers and coatings engineered for healthcare applications without the use of per- and polyfluoroalkyl substances (PFAS). These materials are developed to provide essential chemical resistance, lubricity, and non-stick properties required for surgical tools and fluid handling systems while promoting patient safety and environmental sustainability.
The primary material types of PFAS-free medical device materials include per- and polyfluoroalkyl substances-free medical-grade silicone, per- and polyfluoroalkyl substances-free thermoplastic elastomers, per- and polyfluoroalkyl substances-free polyurethane and polyolefins, and other per- and polyfluoroalkyl substances-free polymers and elastomers. Per- and polyfluoroalkyl substances-free medical-grade silicone refers to silicone materials formulated without intentionally added per- and polyfluoroalkyl substances for use in medical devices and components. These materials are used to manufacture tubing and hoses, seals and gaskets, films and membranes, catheter components, and other per- and polyfluoroalkyl substances-free medical components and are distributed through direct sales, distributors and suppliers, online sales, and other distribution channels. They find application in cardiovascular devices, respiratory and anesthesia devices, drug delivery systems, surgical instruments and implants, and others, serving end users including medical device manufacturers, medical component manufacturers, contract development and manufacturing organizations, research and development organizations, and others.
Tariffs are influencing the Per-and polyfluoroalkyl substances (PFAS)-free medical device materials market are increasing the cost of imported specialty polymers, medical-grade coatings, chemical inputs, and processing equipment required to manufacture PFAS-free medical components. This is raising production costs and potentially delaying the adoption of alternative materials, particularly in regions dependent on imported specialty chemicals and medical manufacturing inputs such as North America, Europe, and Asia-Pacific. Material-intensive segments including PFAS-free medical-grade polymers, coatings, tubing, seals, and fluid handling components are most affected due to global supply chain dependencies. However, tariffs are also encouraging domestic material production, regional supplier diversification, and localized manufacturing of PFAS-free medical components, supporting long-term supply chain resilience and sustainable healthcare manufacturing.
The per-and polyfluoroalkyl substances (PFAS)-free medical device materials market research report is one of a series of new reports from The Business Research Company that provides per-and polyfluoroalkyl substances (PFAS)-free medical device materials market statistics, including per-and polyfluoroalkyl substances (PFAS)-free medical device materials industry global market size, regional shares, competitors with a per-and polyfluoroalkyl substances (PFAS)-free medical device materials market share, detailed per-and polyfluoroalkyl substances (PFAS)-free medical device materials market segments, market trends and opportunities, and any further data you may need to thrive in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials industry. This per-and polyfluoroalkyl substances (PFAS)-free medical device materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The per-and polyfluoroalkyl substances (PFAS)-free medical device materials market size has grown rapidly in recent years. It will grow from $0.94 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to increasing regulatory scrutiny of PFAS use, rising awareness of PFAS-related health concerns, growing demand for safer medical device materials, increasing need for chemical-resistant medical components, rising adoption of environmentally preferable healthcare materials.
The per-and polyfluoroalkyl substances (PFAS)-free medical device materials market size is expected to see rapid growth in the next few years. It will grow to $2.16 billion in 2030 at a compound annual growth rate (CAGR) of 18.2%. The growth in the forecast period can be attributed to growing demand for PFAS-free medical polymers and coatings, increasing adoption of sustainable medical device materials, rising demand for non-stick alternatives in surgical applications, expanding use of PFAS-free materials in fluid handling systems, and growing preference for environmentally sustainable healthcare products. Major trends in the forecast period include increasing adoption of PFAS-free medical device materials, rising demand for non-toxic medical material alternatives, growing use of PFAS-free polymers in surgical instruments, increasing demand for chemical-resistant medical materials, and rising adoption of PFAS-free coatings for fluid handling systems.
The increasing regulatory scrutiny of PFAS across medical-device supply chains is expected to propel the growth of the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market in the coming years. Regulatory scrutiny of PFAS refers to increased government oversight of the production, use, import, disclosure, and disposal of materials containing per- and polyfluoroalkyl substances. This scrutiny is intensifying due to concerns regarding environmental persistence, potential health impacts, and PFAS emissions throughout product life cycles. PFAS-free medical device materials enable manufacturers to substitute fluorinated substances in tubing, seals, membranes, coatings, and device housings while reducing regulatory and supply-related risks. For instance, in August 2025, according to the European Chemicals Agency, a Finland-based government agency, the updated PFAS restriction proposal covered 22 sector categories, including medical devices and other medical applications, compared with 14 categories under evaluation in 2024, representing an increase of approximately 57%. Therefore, the increasing regulatory scrutiny of PFAS across medical-device supply chains is driving the growth of the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market.
Major companies operating in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market are focusing on developing advanced solutions, such as internally lubricated PFAS-free engineering compounds, to reduce friction, enhance wear resistance, and ensure reliable performance in moving medical-device components. Internally lubricated PFAS-free compounds use non-fluorinated functional additives incorporated directly into the polymer matrix to deliver long-lasting lubrication without polytetrafluoroethylene or other PFAS components. For instance, in January 2025, Americhem, a US-based polymer materials manufacturer, launched EcoLube MD, a line of PFAS-free internally lubricated compounds developed for medical devices and healthcare applications. The compounds help reduce friction, component wear, and operating noise in minimally invasive surgical devices, syringe pumps, prosthetics, and surgical robots while supporting plastic-to-plastic and plastic-to-metal applications. Additionally, EcoLube MD underwent ISO 10993-5 biocompatibility testing, supporting medical-device manufacturers in improving regulatory readiness, material safety, and long-term component performance.
In January 2025, GEON Performance Solutions, a US-based provider of performance polymer formulations, vinyl and polyolefin technologies, engineered compounds, and contract manufacturing services, acquired Foster Corporation for an undisclosed amount. Through this acquisition, GEON aimed to strengthen its presence in medical materials, expand its PFAS-free and specialty biomedical polymer capabilities, and broaden its production and distribution reach. Foster Corporation is a US-based provider of custom medical compounds, implantable materials, engineered polymers, thermoplastic polyurethane elastomers, and PFAS-free low-friction additive technologies for medical devices.
Major companies operating in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market are Compagnie de Saint-Gobain S.A., SABIC, Celanese Corporation, Kuraray Co. Ltd., Evonik Industries AG, Syensqo SA, Avient Corporation, Victrex plc, Trinseo PLC, Nordson Corporation, Freudenberg Medical LLC, Zeus Company Inc., Teknor Apex Company, Ensinger GmbH, RAUMEDIC AG, Optinova AB, One Medical Extrusion, BioInteractions Ltd., Harland Medical Systems Inc., Medical Surface Inc., Surface Solutions Group LLC, LipoCoat B.V., DynaFlex Technologies Inc.
North America was the dominating region in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the per-and polyfluoroalkyl substances (PFAS)-free medical device materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The per-and polyfluoroalkyl substances (PFAS)-free medical device materials market consists of sales of PFAS-free polycarbonate (PC), PFAS-free PEEK, PFAS-free polyamide (PA) and PFAS-free polyesters (PET/PBT). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Per-And Polyfluoroalkyl Substances (PFAS)-Free Medical Device Materials Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses per-and polyfluoroalkyl substances (pfas)-free medical device materials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for per-and polyfluoroalkyl substances (pfas)-free medical device materials? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The per-and polyfluoroalkyl substances (pfas)-free medical device materials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope are limited to 20% of content and consultant support time is limited to 8 hours.